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recovery in QOL scores over time was deemed statistically 
significant (p<0.0001). A clinically and statistically significant 
improvement in physical (78.7 vs. 87.7, p=0.05), emotional 
(66.5 vs. 78.5, p=0.05) and social functioning (61.5 vs. 82.2) 
was observed in IMRT cohort. The patients treated with IMRT 
had fewer patients having symptoms of appetite loss (30.4 vs. 
12.1,p=0.01) and diarrhea (24 vs. 9;p=0.04). The use of IMRT 
was also associated with reduced lymphedema (15.2 vs 3.2; 
p=0.05). However no difference was observed in sexual and 
global QOL. 
 
Conclusion: Early results show improved functional scales 
and reduced symptom scales with use of postoperative IMRT 
when compared to 3DCRT. Further long term follow up is 
needed to clearly define the impact of IMRT on patient 
reported outcomes.  
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Purpose or Objective: Pelvic radiotherapy (RT) provides 
good local control in women with endometrial cancer (EC), 
but may also cause substantial acute and chronic adverse 
effects, which in turn may reduce patients' (pts) quality of 
life (QoL). 
 
Material and Methods: 293 pts who were treated with 
adjuvant pelvic RT for EC at our department between 2004 
and 2012 were asked to fill in questionnaires regarding their 
QoL (EORTC QLQ-C30, EN24). Median follow-up was 6 years. 
112 pts agreed to participate. 42 (38%) used the vaginal 
dilator (VD; group A) as prescribed, 62 (55%) did not use the 
VD (group B), 8 (7%) preferred not to answer this question. 
The values of the function and symptom scales of the pats 
were statistically analyzed and compared between the two 
groups as well as compared with reported values of normal 
populations. 
 
Results: The values of the function and symptom scales are 
generally lower in our pts compared to an age adapted 
normal population (NP). Pts reported statistically better 
values for sexual interest and sexual activity compared to NP 
(p<.0001), while sexual enjoyment was significantly reduced 
(p<.0001). Vaginal dryness and pain during intercourse 
(p<.00001) were the leading complaints. Sexual interest and 
activity increased with age (p<.0005) in contrast to NP. Pts in 
group A were younger than in group B (p=.016). Group A 
reported significantly less pain in the back and pelvis 
(p=.005) as well as less muscular pain (p=.013). Pts using VD 
>1 year had better values for sexual interest (p=.0022) and 
sexual activity (p=.013) compared to ≤ 1 year. Pts with 
vaginal brachytherapy (IVB) only had a better global health 
status compared to pts with additional external beam RT, 
while IMRT was better than 3D-conformal RT (p<.0017). Pts 
with higher acute GI toxicity reported more chronic GI 
symptoms (p=.002) with diarrhea (p=.009), nausea/vomiting 
(p=.032) as well as poorer social functioning (p=.036). Pts 
with higher acute GU toxicity reported more pain during 
intercourse (p=.044). 
 
Conclusion: Pelvic RT substantially affects QoL even years 
after treatment. Women participating in our study were more 
sexually active than the normal population. Therefore 
sexuality is important for QoL in women after endometrial 
cancer, even at higher age. The vaginal dilator is capable of 
improving chronic pelvic pain, sexual interest and sexual 
activity when used longer than one year. Pts with higher 
acute toxicities also exhibit more chronic problems. IMRT 
seems to be beneficial for long-term QoL. 
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Purpose or Objective: Uterine motion is a challenging issue 
in applying intensity-modulated radiotherapy (IMRT) for 
patients with cervical cancer. In this study we quantified the 
inter-fraction uterus movement during a course of definitive 
radiotherapy (RT) to determine the predictive factors 
affecting uterine motion. 
 
Material and Methods: A total of 343 cone-beam CT 
(CBCT）scans from 43 patients who underwent definitive RT 
were analyzed retrospectively. The median age of the 
patients was 58 years (range, 34-85 years). The FIGO stages 
were as follows: IB1, 9; IB2, 6; IIA, 1; IIB, 12; IIIB, 10; and 
IVA, 5. Cervical and corpus movement (mm) were measured 
for each direction (cranial [C), anterior [A), left [L) and right 
[R) for the uterine corpus; and A, posterior [P), L, and R for 
the cervix） by comparing planning CT and CBCT. The mean 
movement of each patient was analyzed according to the 
following factors: age; tumor stage; BMI; area of visceral fat 
in the umbilical plane, as assessed by CT; circumference of 
abdominal girth; history of abdominal surgery; uterine 
orientation (anteverted or retroverted); size of the uterus; 
tumor diameter; and tumor invasion to the corpus． 
 
Results: The mean movement of the corpus was as follows: 
C, 5.8 mm (range, 0-29.0 mm); A, 5.2 mm (range, 0.3-37.7 
mm); L, 2.4 mm (range, 0-10.6 mm); and R, 2.5 mm (range, 
0-9.2 mm). The mean movement of the cervix was as follows: 
A, 3.2 mm (range, 0-11.4 mm); P, 2.4 mm (range, 0-12.5 
mm); L, 1.5 mm (range, 0-9.2 mm); and R, 1.6 mm (range, 0-
7.3 mm). There was a significant correlation between 
abdominal girth and anterior movement of the corpus (r=-3.6 
and p=0.029). Tumor invasion to the corpus had a negative 
correlation with posterior movement of the cervix with 
marginal statistical significance (p=0.05)． 
 
Conclusion: The study demonstrated that abdominal girth 
and tumor invasion to the corpus were predictive factors of 
uterine motion during definitive RT for patients with cervical 
cancer． 
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Purpose or Objective: The aim of this study is to investigate 
the ADCmean of the primary tumor to evaluate their 
correlations with the recurrence and survival rates in patients 
with primary cervical cancer before and after definitive CRT. 
 
Material and Methods: The data of 44 patients with 
histologically proven squamous cell carcinoma of cervix was 
retrospectively evaluated .All patients had multi-parametric 
pelvic MR imaging (CE-MRI and DW-MRI) and 18F-FDG PET/CT 
for initial staging prior to treatment and also multi-
parametric pelvic MR imaging after treatment at our 
Institution between February 2009 and May 2014. ADC 
response was measured by the proportion of ADC changes 
between pretreatment and posttreatment ADC measured in 
DW-MRI. The patients were divided into groups based on the 
pretreatment and posttreatment ADCmean of the primary 
tumor cutoff values derived from the ROC curves. Disease-
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free survival (DFS) and OS rates were calculated using the 
Kaplan-Meier method. Multivariate analyses were performed 
using the Cox proportional hazards model. 
Results: The median follow-up for all patients and surviving 
patients was 25 months (range, 3–75 months) and 28 months 
(range, 15–75 months), respectively. Post-treatment MRI 
images were taken within a median of 3.2 months (range, 
2.8–4.1 months) after the completion of CRT. At post-
treatment MRI, 41 patients (93%) exhibited a complete 
response. The mean pretreatment and posttreatment 
ADCmean were 0.882±0.096 × 10-3 mm2/sec, 1.159±0.168 × 
10-3 mm2/sec, respectively. Median percent ADC change was 
33.7% (5.0 – 70.0%). The analyses identified pretreatment 
ADCmean of the primary tumor cutoff values of 0.878× 10-3 
mm2/sec for recurrence (area under the curve [AUC] = 0.818, 
p<0.001; 95% CI, 0.690–0.946, sensitivity 86.4%, specificity 
72.7%), posttreatment ADCmean of the primary tumor cutoff 
values of 1.132 × 10-3 mm2/sec for recurrence (AUC = 0.810, 
p<0.001; 95% CI, 0.684–0.936, sensitivity 77.3%, specificity 
72.7%), ADC change cutoff values of 32.8% for recurrence 
(AUC = 0.810, p<0.001; 95% CI, 0.683–0.937, sensitivity 77.3%, 
specificity 68.2%). In a multivariate analysis, pelvic lymph 
node metastasis and pretreatment ADCmean were significant 
prognostic factors for both OS and DFS. Additionally, ADC 
change between pretreatment and posttreatment DW-MRI 
was significant factor for OS. 
 
Conclusion: Our findings provide evidence that 
posttreatment low ADCmean of the primary tumor is a useful 
clinical prognostic biomarker for recurrence and survival in 
patients with cervical cancer. 
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Purpose or Objective: Radiation therapy on the pelvic region 
in women may induce disturbing vaginal irritation impacting 
on patients quality of life. We tested a hyaluronic acid based 
vaginal washing (Justgin) in the prevention of vaginal 
mucositis in patients treated with external beam radiation 
therapy for pelvic neoplasms. 
 
Material and Methods: Fifty eight female patients affected 
by uterine tumors and undergoing radiation therapy on the 
pelvic region were considered for the study. Median age was 
58. Twenty eight patients were affected by endometrial 
cancer, while 30 were affected by cervical cancer. Radiation 
therapy was delivered by 6 MV X ray of a linear accelerator 
with 4 fields 3D conformal radiation therapy with a dose of 
45-50.4 Gy in 25-28 daily 1.8 Gy fractions. Group A (28 
patients) used Justgin every other day, and 30 patients 
(group B) did not use any prophylactic therapy. Patients were 
visited and interviewed about vaginal discomfort or 
symptoms every week. 
 
Results: At the end of radiation therapy 13/28 patients of 
group A and 27/30 of group B, developed vaginal toxicity of 
any grade (p=0.0005). Overall, however the toxicity was mild 
or moderate in all patients. 
 
Conclusion: Our study suggests that a vaginal washing with 
hyaluronic acid (Justgin) can reduce the incidence of the 
vaginal acute symptoms induced by external beam irradiation 
in women affected by uterine cancer. 
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Purpose or Objective: Endometrial cancer (EC) is the leading 
malignant tumour occurring in the female genital tract. 
miRNAs are small non-coding RNAs that have a broad impact 
on cancer progression. The aim of our study was to define 
tissue miRNA-205 expression levels, which could potentially 
serve as a prognostic marker in EC. We investigated miRNA-
205 profiles in regard to clinicopathological characteristics of 
patients treated with adjuvant radiotherapy from 2002 until 
2014. 
 
Material and Methods: Expression profiling of miRNA-205 was 
performed in EC tissues from patients who were submitted to 
adjuvant radiotherapy after hysterectomy, according to the 
International Federation of Gynecology and Obstetrics (FIGO) 
guidelines. 90 patients were included in the study. The 
median follow-up period was 46 months (min.2 
months;max.119 months). We analyzed the paraffin-
embedded tissue samples and identified the areas of EC. We 
extracted total RNA from 90 EC samples. The reference group 
was constituted by 10 paraffin-embedded healthy 
endometrial tissue samples. Spectrophotometric assessment 
of the total RNA concentration was performed. cDNA was 
synthesized from total RNA with high capacity cDNA synthesis 
kit and miRNA-specific primers (miR-205 and internal control 
RNU6b). The expression of the miRNA-205 was determined 
using real-time quantitive PCR. The expression level of 
miRNA-205 was calculated by ∆CT values based on the 
internal control and plotted as relative value (RV). 
 
Results: Our results indicate that the expression of miRNA-
205 was significantly higher in EC samples (p=0,000158). The 
expression of miRNA-205 was differentiated considering 
different grading levels. The lowest miRNA-205 expression 
was observed in grade 3 (p=0,02). There was no correlation 
between FIGO stages of EC and miRNA-205 expression 
(p=0,23). When we divided patients into two subgroups: 
advanced EC (III, IV FIGO) and non-advanced EC (I,II FIGO) it 
turned out that the expression levels of miRNA-205 were 
significantly lower in the advanced EC patients group 
(p<0,045). The miRNA-205 expression was lower when there 
was over 50% invasion of the myometrium (p<0,038). Kaplan-
Meier survival curves were generated to examine the 
relationship between the expression levels of miRNA-205 and 
patient’s survival rate. Its analysis revealed that high levels 
of miRNA-205 are associated with longer survival (fig.1).  
 
 
Conclusion: Increased miRNA-205 expression is a positive 
prognostic factor. Lower levels of miRNA-205 are 
characteristic of more advanced stages of EC. 
 
 
 
